|
|
| | Glecirasib Basic information |
| Product Name: | Glecirasib | | Synonyms: | 7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile;7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1,2-dihydro-1- [4-methyl-2-(1-methylethyl)-3-pyridinyl]-2-oxo-4-[4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-1,8-Naphthyridine-3-carbonitrile;glecirasib [INN];KRAS G12C inhibitor 36;KRAS G12C inhibitor 62;UP75WH4QKM | | CAS: | 2658588-10-2 | | MF: | C31H26ClF4N7O2 | | MW: | 640.03 | | EINECS: | | | Product Categories: | | | Mol File: | 2658588-10-2.mol |  |
| | Glecirasib Chemical Properties |
| Boiling point | 753.0±60.0 °C(Predicted) | | density | 1.50±0.1 g/cm3(Predicted) | | pka | 5.37±0.20(Predicted) |
| | Glecirasib Usage And Synthesis |
| Uses | KRAS G12C inhibitor 62 is a KRAS G12C inhibitor. KRAS G12C inhibitor 62 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021121367A1)[1]. | | IC 50 | KRas G12C | | References | [1] Amin LI, et al. Kras mutant protein inhibitors. Patent WO2021121367A1. |
| | Glecirasib Preparation Products And Raw materials |
|
|
Tag:Glecirasib(2658588-10-2)
Related Product Information
|
|
2-Propen-1-one, 1-[(3S)-4-[(7R)-7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]-
2,7-Diazaspiro[4.4]nonane-2-acetamide, α-cyclopentyl-7-[[(2R,3R)-3-cyclopropyl-1-methyl-2-aziridinyl]carbonyl]-N-[(1R,10S,12S,18S)-1-[5-(4-cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-2,7,8,10,11,12,13,16,17,18,19,21,22,23-tetradecahydro-22,22-dimethyl-13,19-dioxo-2-(2,2,2-trifluoroethyl)-15H-3,5-etheno-14,18-imino-6,10-methano-6H-pyrrolo[3,4-g][1,12,4,18]dioxadiazacyclodocosin-12-yl]-, (αS,5S)-
NAV2729
Y-27632
1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]tetrahydro-
RMC6291
|